## **ORIGINAL RESEARCH ARTICLE**

RUNNING HEAD: Physical activity and incident CVD in women with novel risk factors

## TITLE: Association between physical activity and risk of incident cardiovascular disease in women with novel risk factors: evidence from the UK Biobank cohort

Authors: Zhaleh Ataei<sup>1,2</sup>, Leah Wright<sup>1,2</sup>, Sergio Ruiz-Carmona<sup>1,3</sup>, Erin J Howden<sup>1,2</sup>

#### Affiliations:

<sup>1</sup>Baker Heart and Diabetes Institute, Melbourne, Australia
<sup>2</sup>Baker Department of Cardiometabolic Health, The University of Melbourne
<sup>3</sup>Centre for Health Analytics, Melbourne Children's Campus, Melbourne, Australia

#### **Corresponding Author**

Dr Erin J Howden Cardiometabolic Health and Exercise Physiology Laboratory Baker Heart and Diabetes Institute 75 Commercial Road Melbourne, 3004, Australia Email: erin.howden@baker.edu.au

#### **1 ABSTRACT**

Background: Previous evidence demonstrates an increased risk of incident cardiovascular
disease (CVD) in women with early menopause and/or adverse pregnancy outcomes. It also
suggests an inverse association between physical activity and risk of incident CVD. However,
this association in women with novel risk factors have not been evaluated. Therefore, we
aimed to address this hypothesis.

7 Methods: We explored the data of 253,300 women without a history of CVD or life limiting 8 conditions from the UK Biobank cohort, we further stratified women with a history of early 9 menopause and/or complicated pregnancy to investigate how the risks affect indent CVD in 10 women. We defined early menopause as any history of natural or surgical (bilateral 11 oophorectomy) menopause < 47 years and adverse pregnancy outcomes as a history of 12 gestational diabetes, hypertensive disorders of pregnancy, stillbirth or  $\geq$  two miscarriages. We 13 then classified women into three categories of physical activity based on their responses to 14 the International Physical Activity Questionnaire. Women with a total MET-min/week of  $\geq$ 15  $3000, \ge 600$  and < 600 were categorised into high, moderate, and low levels of physical 16 activity, respectively. We also assessed the dose-response interaction between physical activity and risk of incident CVD (heart failure (HF), arrhythmia, coronary heart disease 17 18 (CHD), and stroke) in our population and adjusted all the models for potential CVD risk 19 factors.

Results: During a median follow-up of 13 years, we found a significant increased risk of
incident HF, arrhythmia and CHD in women with early menopause/complicated pregnancy,
compared to women without these risk factors. Higher levels of physical activity reduced the
risk of incident HF (HR 0.81, 95% CI 0.67 0.97) and arrhythmia (HR 0.84, 95% CI 0.75
0.94), compared to a low levels. Moreover, a moderate level of physical activity attenuated

25	the risk of incident arrhythmia (HR 0.82, 95% CI 0.74 0.92). However, no significant			
26	associations were found between physical activity risk of incident stroke or CHD.			
27	Conclusion: Our study indicates that higher levels of PA significantly attenuate the risk of			
28	HF and arrhythmia in women with novel risk factors and should be recommended to women			
29	to reduce their increased risk of CVD.			
30				
31	Keywords: pregnancy, menopause, pregnancy complications, primary prevention, exercise,			
32	cardiovascular disease			
33				
34				
35				
36				
37				
38				

#### **39 INTRODUCTION**

40 Cardiovascular disease (CVD) is the most common cause of mortality among women<sup>1</sup>. Despite recognition that gender and sex are important drivers of CVD risk, there remains an 41 42 unmet need to understand what the female specific drivers of CVD outcomes and potential 43 impacts of preventative approaches are. Some traditional risk factors, including diabetes, smoking and obesity, put women at higher risk of developing CVD than men<sup>1-3</sup>. The risk of 44 45 developing coronary heart disease (CHD) conferred by obesity and cigarette smoking is greater in women compared to men by 18% and 25%, respectively<sup>4</sup>. Moreover, women with 46 diabetes are at 44% higher risk of incident CVD compared to men.<sup>2</sup> In addition, some 47 48 unmodifiable or less modifiable stages in women's lives, like early menopause and complicated pregnancy, make them even more vulnerable to CVD.<sup>5,6</sup> According to previous 49 studies, complicated pregnancy and early menopause affect up to  $25\%^7$  and  $\sim 10\%^8$  of 50 51 women, respectively. However, currently there is poor recognition of these risk factors to 52 overall CVD risk stratification and limited evidence of effective prevention approaches.

53 Physical activity is the cornerstone of CVD prevention. It reduces the risk of incident 54 CVD and attenuates the harmful effects of other adverse behaviours, such as inappropriate sleep time or high sedentary behaviour, on cardiovascular health.<sup>9-11</sup> Despite additional risk 55 56 factors in women, they tend to be less active and are more sedentary than men (33.2% inactivity in women vs 29.9% in men)<sup>2</sup>. Physical activity is critical to preventing CVD in this 57 large population. However, the effects of physical activity on the risk of incident CVD in 58 59 women with novel risk factors, including early menopause and complicated pregnancy, has 60 yet to be explored. Determining if physical activity is beneficial in this setting will have 61 important public health implications, since engaging in physical activity is among the most 62 simple and accessible methods to prevent CVD. Our aims were two-fold: firstly, to determine how female-specific risk factors influenced rates of CVD in women in the UK Biobank 63

64 cohort. Secondly, to understand how physical activity modifies the increased risk of CVD in 65 women with novel risk factors and to explore what the ideal level of physical activity is 66 required to prevent developing CVD in this population. We hypothesised that physical 67 activity would be a modifier of CVD outcomes in women with female-specific risk factors.

#### 68 METHODS

69 Study design: The UK Biobank is a large prospective cohort study involving over 500,000 70 participants enrolled from 2006-2010 (Northwest Multicentre Research Ethics Committee 71 (11/NW/0382), Resource number 55469)). At baseline, participants were aged 40-69 years 72 old and assessed in various centres across England, Wales and Scotland and were followed up for different outcomes through linkages to national datasets. <sup>12</sup>. Women with a previous 73 74 history of CVD (N=8813), including heart failure (HF), coronary heart disease (CHD), 75 arrhythmia, ischemic stroke, or any congenital heart disease were excluded from the study 76 (Figure 1). We also excluded women with conditions that reduced their projected life 77 expectancy to less than three years (Alzheimer's disease, kidney failure, chronic obstructive 78 pulmonary disease (COPD), and liver failure, N=3420). Information regarding the exact 79 conditions and their related ICD-10 codes can be found in the supplementary section. The 80 remaining 253,300 women were included in our study. Our analysis was divided into two 81 stages to assess our aims and hypothesis: 1) To assess how novel risk factors impact the risk 82 of developing CVD in women; and 2) To investigate how engaging in different levels of PA 83 interacts with incident CVD in women with novel risk factors. For our second stage, we 84 excluded women without a history of early menopause or complicated pregnancy in addition 85 to those with missing physical activity data or responses that were considered as outliers according to guidelines<sup>13</sup>, giving us a final sample size of 40,952 women (Figure 1). 86

87

#### 88 Physical Activity Assessment

89 Physical activity was assessed according to the participants' self-reported responses to the International Physical Activity Questionnaire (IPAQ)<sup>14</sup>. Individuals responded to questions 90 regarding the amount and type of physical activity they engaged in the last seven days, 91 92 including leisure time, domestic and gardening, as well as work and transport-related physical 93 activity. A "high level" of physical activity was defined as achieving  $\geq$  3000 MET-min/week 94 with a combination of different intensity activities or achieving  $\geq 1500$  MET-min/week with 95 vigorous intensity activities. A moderate level of physical activity was defined as engaging in 96 vigorous-intensity physical activity of  $\geq 20 \text{ min/day}$  for  $\geq$  three days/week or doing a 97 moderate-intensity activity for  $\geq$  five days/week and/or walking of  $\geq$  20 min/day or achieving 98  $\geq$  600 MET-min/week by doing a combination of different intensity activities.

99

#### 100 Novel Risk factors:

101 We defined novel risk factors as any history of early onset menopause (any natural or surgical 102 (bilateral oophorectomy) menopause earlier than 47 years) and/or complicated pregnancy 103 (positive history of one or more of the following: gestational diabetes, hypertensive disorders of pregnancy, stillbirth, and/or two or more miscarriages).<sup>6,15</sup> Data regarding the number of 104 105 miscarriages and stillbirths and the age of menopause were extracted from the self-reported 106 questionnaires. Gestational diabetes was defined based on self-reported data and/or related 107 ICD-10 codes. The data regarding hypertensive disorders of pregnancy were determined by 108 ICD-10 codes.

109

#### 110 Endpoints:

We defined the primary endpoints of this study as diagnosis of HF, CHD, arrhythmia, or ischemic stroke. All the events were reported using ICD-10 codes based on the data from hospitals/clinics (see table S1 supplementary material for complete list). If more than one

event occurred to a participant, we only counted the first one. The number of events for each endpoint followed this rule, and only one event per participant was counted. Time to event for each participant was taken from the date of birth and censored at the date associated with the development of each endpoint or date of death or the date of their last follow-up session, whichever came first.

119

#### 120 Covariates:

We adjusted the results for CVD risk factors, including age, smoking status, obesity, alcohol consumption, diabetes mellitus, hypertension, dyslipidaemia, and history of cancer. Data regarding the smoking status and alcohol intake frequency (how many times per day, week, or month) were obtained from self-reported questionnaires. Obesity was defined as BMI  $\geq$ 30, calculated based on the participants' responses to height and weight at their baseline visits. Diagnosis of hypertension, diabetes, dyslipidaemia, and cancer were defined by at least one of the related ICD-10 codes (supplementary section).

128

#### 129 Statistical analysis:

130 We used Cox proportional hazard models to estimate the hazard ratios (HRs) and 95% 131 confidence intervals (CIs) for incident CVD among women with and without novel risk 132 factors. To determine how different levels of physical activity attenuate the risk of incident 133 CVD we compared the effects of moderate and high levels of physical activity on the risk of 134 incident CVD to the low-level physical activity in women with novel risk factors. Cox 135 proportional hazard models were used to calculate the new hazard ratios and 95% confidence 136 intervals. We evaluated the relationship between physical activity as a continuous variables 137 and incident CVD with cubic spline models. We performed all statistical analyses with R 138 version 4.2.1.

139

Study ethics: The UK Biobank received ethical approval from the Northwest Multicentre
Research Ethics Committee (11/NW/0382). All participants gave written informed consent.
This study has been conducted using the UK Biobank Resource under application number
55469.

144 **RESULTS** 

145 Baseline characteristic. Our study consisted of 253,300 women without a history of CVD or 146 life limiting conditions from the UK Biobank cohort. Baseline characteristics of the included 147 women are presented in table 1. The mean age at study entry was  $57 \pm 8$  and  $56 \pm 8.0$  years in 148 women with and without novel risk factors, respectively. Overall, women without novel risk 149 factors tended to be healthier, compared to women experiencing novel risk factors. Women 150 with novel risk factors were more likely to smoke, and have obesity, diabetes, hypertension, 151 dyslipidaemia, and increased incidence of past cancer. Of the 55,930 women with novel risk 152 factors, 23,627 had a history of complicated pregnancy, and 35,838 experienced early 153 menopause. There was overlap in novel risk factors in 3535 women. The median follow up 154 was 13 years in which there were 8833 incidence CVD events in women with novel risk 155 factors' arm and 21804 in women with no novel risk factors (table 2). The incidence of CVD 156 event rates were higher for each condition of interest among women with novel risk factors 157 compared to those without these risk factors.

158

#### 159 Interaction between novel risk factors and CVD outcomes

In adjusted models, women with a history of early menopause had a significant increase in
the risk of incident HF (HR 1.16, 95% CI 1.08 1.25), CHD (HR 1.15, 95% CI 1.10 1.20),
arrhythmia (HR 1.09, 95% CI 1.04 1.14) and ischemic stroke (HR 1.18, 95% CI 1.07 1.29),
compared to women without this risk factor. Similarly, women with a history of complicated

pregnancy had a significantly higher risk of incident HF (HR 1.11, 95% CI 1.01 1.22), CHD
(HR 1.17, 95% CI 1.11 1.23) and arrhythmia (HR 1.07, 95% CI 1.01 1.13), compared to ones
without complicated pregnancy. However, there was no increased risk of ischemic stroke (HR
1.09, 95% CI 0.97 1.23) in the adjusted models.

168

## 169 Physical activity and attenuation of heart failure risk in women with novel risk factors

170 In the unadjusted models, there was a significant association between physical activity levels 171 and risk of incident HF demonstrating that both moderate (HR 0.69, 95% CI 0.59 0.82) and 172 high (HR 0.59, 95% CI 0.49 0.70) levels of physical activity reduce the risk of incident HF 173 significantly, compared to a low level of physical activity-. However, after adjusting for 174 confounders, only the association between a high level of physical activity and risk of 175 developing HF remained significant (HR 0.81, 95% CI 0.68 0.97) (Figure 2). Dose-response 176 models also showed a reduced risk of HF at a MET-min/week of 3000 (HR 1.10, 95% CI 177 0.94 1.28), compared to the baseline MET-min/week of 0 (HR 1.37, 95% CI 1.07 1.76) 178 (Figure 6A).

179

### 180 Physical activity and attenuation of arrhythmia risk in women with novel risk factors

In the unadjusted models, moderate (HR 0.69, 95% CI 0.62 0.77) and high (HR 0.67, 95% CI 0.60 0.75) levels of physical activity reduced the risk of arrhythmia, compared to low levels of physical activity. After adjusting for confounders, we observed a non-linear association in which the risk of arrhythmia decreased by 18% and 16% with moderate and high levels of physical activity, respectively (Figure 3). The dose-response association, demonstrated a lower risk of arrhythmia at MET-min/week of 3000 (HR 1.06, 95% CI 0.96 1.16) and 600 (HR 1.13, 95% CI 1.06 1.21), compared to 0 (HR 1.35, 95% CI 1.15 1.59) (Figure 6B).

# 189 Physical activity and attenuation of coronary heart disease and stroke risk in women190 with novel risk factors

In the unadjusted models, higher levels of physical activity reduced the risk of incident CHD compared to a low level of physical activity; however, adjusting the models for confounders attenuated the effects (Figures 4). Similarly, the association between physical activity and risk of incident stroke was consistent with that observed for CHD and after adjusting for confounders, there was no statistically significant relationship between risk of incident stroke and physical activity (Figures 5).

197

## 198 Impact of traditional risk factors on CVD outcomes in women with novel risk factors

199 In our multivariable models, traditional risk factors including hypertension and dyslipidaemia 200 were significantly associated with increased risk across all cardiovascular outcomes. 201 Hypertension demonstrated the strongest association with HF (HR 3.99, 95% CI 3.38 4.72), 202 arrhythmia (HR 2.94, 95% CI 2.67 3.24) and stroke (HR 3.01, 95% CI 2.45 3.69) compared 203 to other risk factors (Figures 2,3,5). While for CHD, dyslipidaemia (HR 3.90, 95% CI 3.58 204 4.24) emerged as the most significant determinant (Figure 4). Other factors, including 205 diabetes, history of cancer, smoking and obesity were also included in the analysis; however, 206 their associations with cardiovascular outcomes were less pronounced (Figure 2-5).

207

#### 208 DISCUSSION

The principal new findings in the new study are as follows: women with a history of novel CVD risk factors experience a higher frequency of CVD outcomes and have a higher burden of traditional CV risk factors than women without novel risk factors. Further in this cohort of higher risk women we found that higher levels of physical activity attenuated the risk of incident HF and arrythmia, but not CHD or ischemic stroke. These findings have important

implications for public health recommendations for physical activity and highlight a high-risk group who could benefit from more targeted primary prevention strategies to increase physical activity levels in this population. Indeed, our analysis of the dose effect of physical activity on outcomes, identified that 3000 met minutes per week, which is consistent with current physical activity guidelines, reduced the risk of HF and arrythmia.

219

220 Both early menopause and complicated pregnancy are recognized contributors to an elevated 221 risk of CVD. Although a multitude of female-specific factors have been labelled differently in 222 many different studies, a consistent finding has been that female factors influence CVD outcomes, primarily through hormonal changes and cardiometabolic risk factors.<sup>6,16</sup> The 223 224 increased risk of CVD associated with early menopause is largely attributed to the premature loss of estrogen, a protective factor against CVD<sup>16</sup>. Consistent with these established 225 226 mechanisms, our data showed that early menopause increased the risk of incident HF, CHD, 227 arrhythmia, and stroke by 16%, 15%, 9%, and 18%, respectively. Similarly, pregnancy 228 complications, including miscarriages  $\geq 2$ , stillbirth, gestational diabetes, and hypertensive disorders of pregnancy, were associated with an increase in the risk of incident HF (11%), 229 230 CHD (17%), and arrhythmia (7%). Women with a history of complicated pregnancy have an increased risk of developing CVD risk factors and later CVD<sup>17</sup>. The mechanism for this is 231 232 likely multifactorial, with the development of CV risk factors mediated by a combination of 233 lifestyle factors and vascular and metabolic dysfunction.

234

Accordingly, understanding the role of traditional risk factors is crucial for evaluating cardiovascular outcomes in this population. Hypertension is a strong CVD risk factor for premature mortality in women<sup>18</sup> and women who have a history of hypertensive disorder of pregnancy have an increased risk of developing hypertension<sup>19</sup>. In turn this relationship

239 mediates the association with both HF and CAD in this patient group. Similarly, 240 hyperlipidaemia is the driving factor of CHD development, without which the disease would not manifest.<sup>20</sup> These patterns were evident in our study where hypertension emerged as the 241 242 strongest contributor to an increased risk of HF, arrhythmia and ischemic stroke; while 243 dyslipidaemia was the primary predictor of the risk of incident CHD, compared to other risk 244 factors (Figure 2-5). These findings underscore the multifaceted nature of CVD and the 245 importance of awareness of both traditional and novel risk factors to improve cardiovascular outcomes in this population. Emerging evidence suggest that optimal dosing of guideline 246 directed medical therapy may differ for women<sup>21</sup> and less women receive guideline directed 247 therapy $^{22}$ . While we were unable to evaluate the usage of cardioprotective therapy in our 248 249 study, our finding suggests a multi-dimensional approach is required to attenuate the 250 increased risk of CVD.

251

252 This is the first study to our knowledge that has evaluated whether lifestyle factors influence 253 CVD outcomes in women with novel risk factors. There is strong rationale for the promotion 254 of physical activity to all women to mitigate CVD risk, but individuals with increased risk may benefit from more tailored intervention. Interestingly current physical activity guidelines 255 are largely derived from studies of males<sup>23</sup> and despite the growing understanding of sex and 256 gender specific differences in responses to exercise<sup>24,25</sup>. there are no specific physical activity 257 258 recommendations for healthy women, nor women with a high CVD risk. Therefore, studies 259 that focus specifically on women and evaluate higher risk groups of women are essential to 260 determine the relevance and effectiveness of current physical activity guideline and their 261 effectiveness in preventing CVD. In this cohort we found that higher levels of physical 262 activity lowered the risk of HF and arrhythmia incidence in women with novel risk factors. 263 After adjusting for other confounders only the higher level of physical activity was protective

for women developing HF. This is consistent with meta-analysis that reported that higher levels of physical activity are required to prevent HF <sup>26</sup>. Conversely, in our adjusted models both moderate and higher levels of physical activity lowered the risk of arrhythmia, which is also consistent with prior findings demonstrating that more physically activity individuals have a lower risk of arrhythmia<sup>27</sup>.

269

270 Previous studies have established the protective effects of physical activity on various 271 cardiovascular outcomes. High levels of physical activity have consistently been associated 272 with a significantly reduced risk of incident HF, with research indicating a 35% lower risk 273 among individuals with the highest level of physical activity (four times guidelines recommended level), compared to a low levels.<sup>28</sup> We demonstrated that a high level of 274 physical activity (achieving ≥ 3000 MET-min/week through a combination of different 275 276 intensities of physical activity) is protective against developing HF, compared to a low level 277 of physical activity. On the other hand, our data showed both moderate (≥ 600 MET-278 min/week) and high levels of physical activity attenuate the risk of arrhythmia. Observing a 279 non-linear relationship, our findings demonstrated that a moderate level of physical activity was the optimal level to prevent developing arrhythmia and no further significant risk 280 281 reduction was achieved in women with a high level of physical activity, compared to those with a moderate level. This finding has also been observed elsewhere<sup>29</sup>. In contrast, a study 282 283 from Azarbal et al., focusing on the data of nearly 82,000 postmenopausal women without a 284 history of AF, observed a significant inverse association between a high level of recreational physical activity (> 9 MET-h/week) and risk of incident  $AF^{30}$ . Variations in study population, 285 286 domains of physical activity (recreational vs all domains) and different confounding factors 287 might be the reason of having varied findings among the studies.

289 Interestingly, for CHD and stoke, no significant associations were observed after adjusting for potential confounding factors. While prior studies have observed that moderate <sup>31</sup> and high <sup>32</sup> 290 <sup>33</sup> levels of physical activity attenuate the risk of incident CHD and stoke, our findings with a 291 292 follow up of 13 years do not support this. It is possible that the discrepancy in findings with 293 prior work is due to the shorter follow up in our study and difficulty in identifying patients 294 with CHD or stoke prior to experiencing an event. For example, an arrhythmia can be 295 detected through ECG screening, while an exercise or pharmacological stress test would be 296 required to detect CHD and this is not routinely performed in HD and this is not routinely 297 performed in *asymptomatic* people. Whereas, Hummel et al. found that higher levels of total 298 physical activity(MET-h/day > 3.6) in women had a significantly lower risk of experiencing a myocardial infarction, compared to a low level of physical activity (MET-h/day  $\leq 1.6$ )<sup>32</sup>. 299 300 Apart from differences in study population, variations in the measurement of physical activity 301 further complicate comparison between the studies.

302

303 The cardiovascular benefits of physical activity are largely due to the beneficial effects on 304 CVD risk factors e.g. hypertension, dyslipidaemia, glycaemic control and optimal body composition, however, some of the mechanisms of benefits are yet to be determined <sup>34</sup>. 305 306 Sustaining higher levels of physical activity over a lifetime is likely to have provide critical 307 cardioprotection for maintaining cardiovascular health women. Indeed, we have shown in 308 women who initiate exercise training in early and mid-life, prior to menopause that exercise training reduces ventricular stiffness and improves cardiorespiratory fitness<sup>25,35</sup> whereas 309 310 other evidence suggests that cardiovascular benefits are blunted in women who increase physical activity levels after menopause<sup>36</sup>. Importantly women with a lifelong history of 311 312 increased physical activity, consistent with the levels observed to be protective in this cohort 313 of women with novel risk factors, had superior cardiac function and cardiorespiratory fitness

than similar aged and younger sedentary women<sup>37</sup>. Physical activity can also contribute to lowering CVD risk, through better metabolic health with improved insulin sensitivity and glycaemic control <sup>38</sup>, and better body composition<sup>39</sup>. The consequential impacts of which decreases the risk of increased adiposity which has been shown to directly increase inflammation and alter autonomic tone, thereby raising the risk of AF <sup>26,30,40</sup> and HF<sup>41</sup>.

319

#### 320 Strengths and limitations

321 To our knowledge, this is the first and largest study to assess the interaction between physical 322 activity and risk of incident CVD in women with novel risk factors; however, some 323 limitations must be acknowledged. The use of self-reported data may be subject to recall bias 324 and there is a tendency to overestimate physical activity levels. We chose to evaluate total 325 physical activity levels to reflect the overall weekly behaviour, recognising that for women in 326 particular physical activity may be performed outside of structured settings. Physical activity behaviour was only assessed at baseline in our study, and therefore there may have been 327 328 important changes to physical activity during follow-up that could have influenced our 329 findings. Menopause history was also reported by self-report. Furthermore, while we adjusted 330 our results for several key CVD risk factors, other risk factors, including female specific such 331 as preterm delivery, intrauterine growth restriction and small for gestational age, or other risk 332 factors including diet, sleeping habits and sedentary behaviour should be considered in future 333 research. Further, the UK Biobank cohort may not be reflective of the general population, 334 however there is greater than 50% participation from women which strengthens the 335 generalisability for the focus of this study. Finally, in future studies it would be important to 336 understand how novel risk factors contribute to different subtypes of HF e.g. heart failure with preserved ejection fraction which is 2-fold more common in women<sup>42</sup> and what effects 337 338 physical activity have in these populations.

339

#### 340 CONCLUSION

341 Our study highlights the effect of novel risk factors on CVD outcomes in women, while also 342 presenting the protective effect of physical activity, specifically on incident HF and 343 arrhythmia. We showed that guideline recommended physical activity levels of 150 minutes 344 of moderate-vigorous physical activity or > 3000 met-minutes per week can prevent 345 arrhythmia; however, to achieve the maximum protective benefit of physical activity against 346 HF, women with novel risk factors need to engage in physical activity at twice the 347 recommended levels. These findings reinforce the critical role of physical activity in 348 mitigating cardiovascular risks and underscores the importance of educational campaigns 349 designed for women with a history of novel risk factors to inform women about the potential 350 benefits of physical activity and encourage them to be active. Moreover, our findings 351 highlight the need for more precise guidelines regarding the optimal level of physical activity 352 to effectively reduce the risk of incident CVD, specifically in this population.

353

#### **354 DECLARATIONS**

Authors' Disclosures of Potential Conflicts of Interest. All other authors have no relevant
 financial or non-financial interests to disclose.

357 Data Sharing Statement. This research was conducted using the UK Biobank Resource
 358 (<u>http://www.ukbiobank.ac.uk</u>/) under application 55469. Data from the UK Biobank is
 359 accessible to eligible researchers via applying to www.ukbiobank.ac.uk.

360 Funding Sources. EJH was supported by an Australian National Heart Foundation Future361 Leader Fellowship (ID: 102536).

362 Author Contributions.

363 Conception and design: EJH, LW, SRC

- 364 Collection and assembly of data: ZA
- 365 Data analysis and interpretation: ZA, EJH, LW, SRC
- 366 <u>Manuscript writing:</u> ZA (initial draft), All authors (revisions)
- 367 <u>Final approval of manuscript:</u> All authors
- 368 Accountable for all aspects of the work: All authors

#### 370 References

- 371 1. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, Guerrero 372 M, Kunadian V, Lam CSP, Maas A, et al. The Lancet women and cardiovascular 373 disease Commission: reducing the global burden by 2030. Lancet. 2021;397:2385-374 2438. doi: 10.1016/s0140-6736(21)00684-x
- 375 2. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular Disease in 376 Women: Clinical Perspectives. Circ Res. 2016;118:1273-1293. doi:
- 377 10.1161/circresaha.116.307547
- 378 3. Sattar N, Rawshani A, Franzén S, Rawshani A, Svensson AM, Rosengren A, McGuire 379 DK, Eliasson B, Gudbjörnsdottir S. Age at Diagnosis of Type 2 Diabetes Mellitus and 380 Associations With Cardiovascular and Mortality Risks. Circulation. 2019;139:2228-381 2237. doi: 10.1161/circulationaha.118.037885
- 382 4. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart 383 disease in women compared with men: a systematic review and meta-analysis of 384 prospective cohort studies. Lancet. 2011;378:1297-1305. doi: 10.1016/s0140-385 6736(11)60781-2
- 386 Roa-Díaz ZM, Raguindin PF, Bano A, Laine JE, Muka T, Glisic M. Menopause and 5. 387 cardiometabolic diseases: What we (don't) know and why it matters. Maturitas. 388 2021;152:48-56. doi: 10.1016/j.maturitas.2021.06.013
- 389 Täufer Cederlöf E, Lundgren M, Lindahl B, Christersson C. Pregnancy Complications 6. 390 and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study. J Am 391 Heart Assoc. 2022;11:e023079. doi: 10.1161/jaha.121.023079
- 392 Khan SS, Petito LC, Huang X, Harrington K, McNeil RB, Bello NA, Bairey Merz 7. 393 CN, Miller EC, Ravi R, Scifres C, et al. Body Mass Index, Adverse Pregnancy 394 Outcomes, and Cardiovascular Disease Risk. Circ Res. 2023;133:725-735. doi: 395 10.1161/circresaha.123.322762
- 396 8. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, 397 Limacher MC, Manson JE, Stefanick ML, Allison MA, et al. Menopause Transition 398 and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A 399 Scientific Statement From the American Heart Association. Circulation. 400 2020;142:e506-e532. doi: doi:10.1161/CIR.000000000000912
- 401 9. Ekelund U, Steene-Johannessen J, Brown WJ, Fagerland MW, Owen N, Powell KE, 402 Bauman A, Lee IM. Does physical activity attenuate, or even eliminate, the 403 detrimental association of sitting time with mortality? A harmonised meta-analysis of 404 data from more than 1 million men and women. Lancet. 2016;388:1302-1310. doi: 405 10.1016/s0140-6736(16)30370-1
- 406 10. Ekelund U, Brown WJ, Steene-Johannessen J, Fagerland MW, Owen N, Powell KE, 407 Bauman AE, Lee IM. Do the associations of sedentary behaviour with cardiovascular 408 disease mortality and cancer mortality differ by physical activity level? A systematic 409 review and harmonised meta-analysis of data from 850 060 participants. Br J Sports 410 Med. 2019;53:886-894. doi: 10.1136/bjsports-2017-098963
- 411 Chen LJ, Hamer M, Lai YJ, Huang BH, Ku PW, Stamatakis E. Can physical activity 11. 412 eliminate the mortality risk associated with poor sleep? A 15-year follow-up of 413 341,248 MJ Cohort participants. J Sport Health Sci. 2021. doi:
- 414 10.1016/j.jshs.2021.03.001
- 415 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, 12. 416 Green J, Landray M, et al. UK biobank: an open access resource for identifying the 417 causes of a wide range of complex diseases of middle and old age. PLoS Med. 418 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779

- 419 13. International Physical Activity Questionnaire. 420 https://sites.google.com/view/ipaq/score. 421 Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt 14. 422 M, Ekelund U, Yngve A, Sallis JF. International physical activity questionnaire: 12-423 country reliability and validity. Medicine & science in sports & exercise. 424 2003;35:1381-1395. 425 15. Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ, Kuh 426 D, Hardy R, Avis NE, et al. Age at natural menopause and risk of incident 427 cardiovascular disease: a pooled analysis of individual patient data. Lancet Public 428 Health. 2019;4:e553-e564. doi: 10.1016/s2468-2667(19)30155-0 429 Yoshida Y, Chen Z, Baudier RL, Krousel-Wood M, Anderson AH, Fonseca VA, 16. 430 Mauvais-Jarvis F. Early Menopause and Cardiovascular Disease Risk in Women With 431 or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women. 432 Diabetes Care. 2021;44:2564-2572. doi: 10.2337/dc21-1107 433 Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, 17. 434 Gunderson EP, Stuart JJ, Vaidya D, Epidemiology ObotAHACo, et al. Adverse 435 Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for 436 Cardiovascular Disease Prevention in Women: A Scientific Statement From the 437 American Heart Association. Circulation. 2021;143:e902-e916. doi: 438 doi:10.1161/CIR.000000000000961 439 Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, Cornelissen V, 18. 440 Diévart F, Ferrini M, Kahan T, et al. Sex differences in arterial hypertension: A 441 scientific statement from the ESC Council on Hypertension, the European Association 442 of Preventive Cardiology, Association of Cardiovascular Nursing and Allied 443 Professions, the ESC Council for Cardiology Practice, and the ESC Working Group 444 on Cardiovascular Pharmacotherapy. European Heart Journal. 2022;43:4777-4788. 445 doi: 10.1093/eurhearti/ehac470 446 19. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM, 447 Natarajan P. Long-Term Cardiovascular Risk in Women With Hypertension 448 During Pregnancy. Journal of the American College of Cardiology. 2019;74:2743-449 2754. doi: doi:10.1016/j.jacc.2019.09.052 450 20. Sallam T, Watson KE. Predictors of cardiovascular risk in women. Womens Health 451 (Lond). 2013;9:491-498. doi: 10.2217/whe.13.44 Agarwal A, Peters SAE, Chandramouli C, Lam CSP, Figtree GA, Arnott C. Guideline-452 21. 453 Directed Medical Therapy in Females with Heart Failure with Reduced Ejection 454 Fraction. Curr Heart Fail Rep. 2021;18:284-289. doi: 10.1007/s11897-021-00524-z 455 22. Sumarsono A, Xie L, Keshvani N, Zhang C, Patel L, Alonso WW, Thibodeau JT, 456 Fonarow GC, Van Spall HGC, Messiah SE, et al. Sex Disparities in Longitudinal Use 457 and Intensification of Guideline-Directed Medical Therapy Among Patients With 458 Newly Diagnosed Heart Failure With Reduced Ejection Fraction. Circulation. 459 2024;149:510-520. doi: 10.1161/circulationaha.123.067489 460 23. Blair SN, LaMonte MJ, Nichaman MZ. The evolution of physical activity 461 recommendations: how much is enough?1234. The American Journal of Clinical 462 Nutrition. 2004;79:913S-920S. doi: https://doi.org/10.1093/ajcn/79.5.913S 463 24. Bassareo PP, Crisafulli A. Gender Differences in Hemodynamic Regulation and 464 Cardiovascular Adaptations to Dynamic Exercise. Curr Cardiol Rev. 2020;16:65-72. 465 doi: 10.2174/1573403x15666190321141856 466 25. Barnes JN, Fu Q. Sex-Specific Ventricular and Vascular Adaptations to Exercise. Adv 467 Exp Med Biol. 2018;1065:329-346. doi: 10.1007/978-3-319-77932-4 21

medRxiv preprint doi: https://doi.org/10.1101/2024.10.14.24315492; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 468 26. Aune D, Schlesinger S, Leitzmann MF, Tonstad S, Norat T, Riboli E, Vatten LJ. 469 Physical activity and the risk of heart failure: a systematic review and dose-response 470 meta-analysis of prospective studies. Eur J Epidemiol. 2021;36:367-381. doi: 471 10.1007/s10654-020-00693-6
- 472 Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME, Verdicchio 27. 473 CV, Hendriks JML, Lau DH, La Gerche A, et al. Association between physical 474 activity and risk of incident arrhythmias in 402 406 individuals: evidence from the 475 UK Biobank cohort. European Heart Journal. 2020;41:1479-1486. doi: 476 10.1093/eurheartj/ehz897
- 477 28. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de 478 Lemos JA, Berry JD. Dose-Response Relationship Between Physical Activity and 479 Risk of Heart Failure: A Meta-Analysis. Circulation. 2015;132:1786-1794. doi: 480 10.1161/circulationaha.115.015853
- 481 Jin MN, Yang PS, Song C, Yu HT, Kim TH, Uhm JS, Sung JH, Pak HN, Lee MH, 29. 482 Joung B. Physical Activity and Risk of Atrial Fibrillation: A Nationwide Cohort Study 483 in General Population. Sci Rep. 2019;9:13270. doi: 10.1038/s41598-019-49686-w
- 484 30. Azarbal F, Stefanick ML, Salmoirago-Blotcher E, Manson JE, Albert CM, LaMonte 485 MJ, Larson JC, Li W, Martin LW, Nassir R, et al. Obesity, physical activity, and their 486 interaction in incident atrial fibrillation in postmenopausal women. J Am Heart Assoc. 487 2014;3. doi: 10.1161/jaha.114.001127
- 488 Armstrong ME, Green J, Reeves GK, Beral V, Cairns BJ. Frequent physical activity 31. 489 may not reduce vascular disease risk as much as moderate activity: large prospective 490 study of women in the United Kingdom. Circulation. 2015;131:721-729. doi: 491 10.1161/circulationaha.114.010296
- 492 32. Hummel M, Hantikainen E, Adami HO, Ye W, Bellocco R, Bonn SE, Lagerros YT. 493 Association between total and leisure time physical activity and risk of myocardial 494 infarction and stroke - a Swedish cohort study. BMC Public Health. 2022;22:532. doi: 495 10.1186/s12889-022-12923-5
- 496 33. Sattelmair JR, Kurth T, Buring JE, Lee IM. Physical activity and risk of stroke in 497 women. Stroke. 2010;41:1243-1250. doi: 10.1161/strokeaha.110.584300
- 498 Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of 34. 499 cardiovascular events: potential mediating mechanisms. Circulation. 2007;116:2110-500 2118. doi: 10.1161/circulationaha.107.729939
- 501 Howden EJ, Sarma S, Lawley JS, Opondo M, Cornwell W, Stoller D, Urey MA, 35. 502 Adams-Huet B, Levine BD. Reversing the Cardiac Effects of Sedentary Aging in 503 Middle Age-A Randomized Controlled Trial: Implications For Heart Failure 504 Prevention. Circulation. 2018;137:1549-1560. doi:
- 505 10.1161/circulationaha.117.030617
- 506 36. Seals DR, Nagy EE, Moreau KL. Aerobic exercise training and vascular function with 507 ageing in healthy men and women. J Physiol. 2019;597:4901-4914. doi: 508 10.1113/jp277764
- 509 Carrick-Ranson G, Howden EJ, Brazile TL, Levine BD, Reading SA. Effects of aging 37. 510 and endurance exercise training on cardiorespiratory fitness and cardiac structure and 511 function in healthy midlife and older women. Journal of Applied Physiology. 512 2023;135:1215-1235. doi: 10.1152/japplphysiol.00798.2022
- 513 38. Thyfault JP, Bergouignan A. Exercise and metabolic health: beyond skeletal muscle. 514 Diabetologia. 2020;63:1464-1474. doi: 10.1007/s00125-020-05177-6
- 515 39. Westerterp KR. Exercise, energy balance and body composition. European Journal of 516 Clinical Nutrition. 2018;72:1246-1250. doi: 10.1038/s41430-018-0180-4

- 517 40. Ofman P, Khawaja O, Rahilly-Tierney CR, Peralta A, Hoffmeister P, Reynolds MR, 518 Gaziano JM, Djousse L. Regular physical activity and risk of atrial fibrillation: a 519 systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2013;6:252-256. 520 doi: 10.1161/circep.113.000147
- Lopez-Jimenez F, Almahmeed W, Bays H, Cuevas A, Di Angelantonio E, le Roux 521 41. CW, Sattar N, Sun MC, Wittert G, Pinto FJ, et al. Obesity and cardiovascular disease: 522 523 mechanistic insights and management strategies. A joint position paper by the World 524 Heart Federation and World Obesity Federation. European Journal of Preventive 525 Cardiology. 2022;29:2218-2237. doi: 10.1093/eurjpc/zwac187
- 526 42. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, 527 Killian JM, Roger VL. A Contemporary Appraisal of the Heart Failure Epidemic in 528 Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine. 2015;175:996-529 1004. doi: 10.1001/jamainternmed.2015.0924

#### **Table 1. Participants Characteristics** 532

		Novel risk factors	Without novel risk factors
		(N=55930)	(N=197370)
General Cha	racteristics		
Age at baselin	ne (year)	$57.3\pm7.6$	$55.8\pm8.0$
Ethnicity, n (%	%)		
White		52209 (93.3)	186,747 (94.6)
Asian		1362 (2.4)	3686 (1.9)
Black		1164 (2.1)	3033 (1.5)
Others		1195 (2.2)	3904 (2.0)
<b>Risk factors</b>			
Smoker, n (%)		31,745 (56.7)	106623 (54.0)
BMI (kg/m2)		$27.4\pm5.2$	$26.8\pm5.0$
Obesity, n (%)		14431 (25.8)	43345 (21.9)
Glucose (mmol/L)		$5.1 \pm 1.1$	$5.0\pm0.99$
HbA1c (mmol/mol)		$36.3\pm6.4$	$35.5\pm5.6$
Diabetes Mel	litus, n (%)	4536 (8.1)	10150 (5.1)
SBP (mmHg)		$138\pm20$	$137\pm20$
DBP (mmHg)		$81 \pm 10$	$81 \pm 10$
Hypertension, n (%)		16,846 (30.1)	45590 (23.0)
Total cholesterol (mmol/L)		$4.8\pm0.9$	$4.7\pm0.9$
LDL cholesterol (mmol/L)		$1.8\pm0.4$	$1.7\pm0.4$
HDL cholesterol (mmol/L)		$1.4\pm0.3$	$1.4 \pm 0.3$
Total triglyceride (mmol/L)		$1.3\pm0.6$	$1.2\pm0.5$
Dyslipidaemia, n (%)		7635 (13.6)	19096 (9.6)
Cancer, n (%)		10272 (18.3)	32691 (16.5)
Physical Acti	ivity		
Summed PA (MET-min/wk)		$2611\pm2575.0$	$2495\pm2437.3$
	Low	7986 (14.3)	28265 (14.3)
IPAQ n (%)	Moderate	18235 (32.6)	66707 (33.8)
	High	17101 (30.6)	59198 (30.0)
	Missing	12608 (22.5)	43200 (21.9)

534 Acronyms: BMI: Body mass index, HbA1c: Haemoglobin A1c, SBP: Systolic blood 535 pressure, DBP: Diastolic blood pressure, LDL: Low-density lipoprotein, HDL: High-density 536 lipoprotein, HRT: Hormone replacement therapy, OCP: Oral contraceptive pills, POP: Progestogen-only pills, PA: Physical activity, IPAQ: International physical activity 537 538 questionnaire.

539

Novel risk factors	Without novel risk factors
(N=55930)	(N=197370)
1374 (2.4)	3318 (1.7)
2699 (4.8)	7104 (3.5)
3963 (6.6)	9449 (4.7)
797 (1.4)	1933 (0.9)
	Novel risk factors (N=55930) 1374 (2.4) 2699 (4.8) 3963 (6.6) 797 (1.4)

#### Table 2. Incidence of CVD Events in women with and without novel risk factors